DBV Technologies Peanut Allergy Patch Meets Primary Endpoint in Trial

Dow Jones

Dec 17, 2025

By Katherine Hamilton

DBV Technologies patch treatment for children allergic to peanuts met its primary endpoint in a Phase 3 trial.

The French biopharmaceutical company said Tuesday 46.6% of children who used the patch, named the Viaskin Peanut, met the treatment responder criteria after 12 months. That compared with 14.8% of children in the placebo group.

Safety results were consistent with previous clinical programs, with the most common adverse effect being mild-to-moderate local skin reactions where the patch was applied.

DBV enrolled 654 children aged 4 to 7 years in the trial.

The company is moving forward with plans to submit a biologics license application for the patch in the U.S. in the first half of next year.

The Food and Drug Administration previously granted breakthrough therapy designation for the patch, and DBV said it expects the license application could be granted priority review.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 16, 2025 16:23 ET (21:23 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2592025937"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592025937\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592025937?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 05:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592025937","market":"hk","top_or_hot":-1,"title":"DBV Technologies Peanut Allergy Patch Meets Primary Endpoint in Trial","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  DBV Technologies patch treatment for children allergic to peanuts met its primary endpoint in a Phase 3 trial. \n</p>\n<p>\n  The French biopharmaceutical company said Tuesday 46.6% of children who used the patch, named the Viaskin Peanut, met the treatment responder criteria after 12 months. That compared with 14.8% of children in the placebo group. \n</p>\n<p>\n  Safety results were consistent with previous clinical programs, with the most common adverse effect being mild-to-moderate local skin reactions where the patch was applied. \n</p>\n<p>\n  DBV enrolled 654 children aged 4 to 7 years in the trial. \n</p>\n<p>\n  The company is moving forward with plans to submit a biologics license application for the patch in the U.S. in the first half of next year. \n</p>\n<p>\n  The Food and Drug Administration previously granted breakthrough therapy designation for the patch, and DBV said it expects the license application could be granted priority review. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2025 16:23 ET (21:23 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DBV Technologies Peanut Allergy Patch Meets Primary Endpoint in Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDBV Technologies Peanut Allergy Patch Meets Primary Endpoint in Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-17 05:23</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  DBV Technologies patch treatment for children allergic to peanuts met its primary endpoint in a Phase 3 trial. \n</p>\n<p>\n  The French biopharmaceutical company said Tuesday 46.6% of children who used the patch, named the Viaskin Peanut, met the treatment responder criteria after 12 months. That compared with 14.8% of children in the placebo group. \n</p>\n<p>\n  Safety results were consistent with previous clinical programs, with the most common adverse effect being mild-to-moderate local skin reactions where the patch was applied. \n</p>\n<p>\n  DBV enrolled 654 children aged 4 to 7 years in the trial. \n</p>\n<p>\n  The company is moving forward with plans to submit a biologics license application for the patch in the U.S. in the first half of next year. \n</p>\n<p>\n  The Food and Drug Administration previously granted breakthrough therapy designation for the patch, and DBV said it expects the license application could be granted priority review. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 16, 2025 16:23 ET (21:23 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DBVT","symbol_name":"DBV Technologies S.A.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2592025937","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592025937","pubTimestamp":1765920180,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"DBV Technologies patch treatment for children allergic to peanuts met its primary endpoint in a Phase 3 trial.The French biopharmaceutical company said Tuesday 46.6% of children who used the patch, named the Viaskin Peanut, met the treatment responder criteria after 12 months. That compared with 14.8% of children in the placebo group.Safety results were consistent with previous clinical programs, with the most common adverse effect being mild-to-moderate local skin reactions where the patch was applied.DBV enrolled 654 children aged 4 to 7 years in the trial.The company is moving forward with plans to submit a biologics license application for the patch in the U.S. in the first half of next year.The Food and Drug Administration previously granted breakthrough therapy designation for the patch, and DBV said it expects the license application could be granted priority review.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DBVT":"DBV Technologies S.A.","DBV":"Invesco DB G10 Currency Harvest Fund","BK4139":"生物科技"},"translate_title":"DBV Technologies花生过敏贴片在试验中达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DBVT":0.9,"DBV":1.5},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  DBV Technologies patch treatment for children allergic to peanuts met its primary endpoint in a Phase 3 trial. \n\n\n  The French biopharmaceutical company said Tuesday 46.6% of children who used the patch, named the Viaskin Peanut, met the treatment responder criteria after 12 months. That compared with 14.8% of children in the placebo group. \n\n\n  Safety results were consistent with previous clinical programs, with the most common adverse effect being mild-to-moderate local skin reactions where the patch was applied. \n\n\n  DBV enrolled 654 children aged 4 to 7 years in the trial. \n\n\n  The company is moving forward with plans to submit a biologics license application for the patch in the U.S. in the first half of next year. \n\n\n  The Food and Drug Administration previously granted breakthrough therapy designation for the patch, and DBV said it expects the license application could be granted priority review. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 16:23 ET (21:23 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}